Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010;20 Suppl 1(Suppl 1):S35-49.
doi: 10.3233/JAD-2010-1400.

Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine

Affiliations
Review

Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine

Sergi Ferré. J Alzheimers Dis. 2010.

Abstract

Caffeine is the most consumed psychoactive drug in the world. It is a non-selective adenosine receptor antagonist that in the brain targets mainly adenosine A1 and A2A receptors. The same as classical psychostimulants, caffeine produces motor-activating, reinforcing and arousing effects. This depends on the ability of caffeine to counteract multiple effects of adenosine in the central ascending neurotransmitter systems. Motor and reinforcing effects depend on the ability of caffeine to release pre- and postsynaptic brakes that adenosine imposes on the ascending dopaminergic system. By targeting A1-A2A receptor heteromers in striatal glutamatergic terminals and A1 receptors in striatal dopaminergic terminals (presynaptic brake), caffeine induces glutamate-dependent and glutamate-independent release of dopamine. These presynaptic effects of caffeine are potentiated by the release of the postsynaptic brake imposed by antagonistic interactions in the striatal A2A-D2 and A1-D1 receptor heteromers. Arousing effects of caffeine depend on the blockade of multiple inhibitory mechanisms that adenosine, as an endogenous sleep-promoting substance, exerts on the multiply interconnected ascending arousal systems. Those mechanisms include a direct A1-receptor mediated modulation of the corticopetal basal forebrain system and an indirect A2A-receptor mediated modulation of the hypothalamic histaminergic and orexinergic systems.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Caffeine targets in the striatal spine modules of the GABAergic enkephalinergic neuron (a) and GABAergic dynorphinergic neuron (b). Adenosine A2A-dopamine D2 receptor heteromers are localized in the dendritic spines of the GABAergic enkephalinergic neuron and adenosine A1-dopamine D1 receptor heteromers are localized in the dendritic spines of the GABAergic dynorphinergic neurons. Presynaptic A2A receptors form heteromers with A1 receptors and are localized in the striatal glutamatergic terminals that make contact with the dendritic spines of the GABAergic dynorphinergic neuron. A1 receptors are also localized in a fraction of dopaminergic terminals (modified from ref. [16]).
Fig. 2.
Fig. 2.
Scheme of the highly interconnected multiple ascending arousal systems, which are all targets of caffeine (see text). BF: area of origin of the corticopetal basal forebrain system; LC: locus coeruleus; LDT and PPT: laterodorsal and pedunculopontine nuclei; TM: tuberomammillary nucleus; Orx: area of origin of the orexinergic system; Thal: thalamus.

Similar articles

Cited by

References

    1. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51, 83–133. - PubMed
    1. Griffiths RR, Juliano LM, Chausmer A (2003) Caffeine: Pharmacology and Clinical Effects. In Principles of Addiction Medicine, Graham AW, Schultz TK, Mayo-Smth MF, Ries RK, Wilford BB, eds, Third Edition, American Society of Addiction Medicine, Chevy Chase, pp. 193–224.
    1. Ferré S (2008) An update on the mechanisms of the psychostimulant effects of caffeine. J Neurochem 105, 1067–1079. - PubMed
    1. Griffiths RR,Woodson PP (1988) Reinforcing effects of caffeine in humans. J Pharmacol Exp Ther 246, 21–29. - PubMed
    1. Mumford GK, Holtzman SG (1991) Qualitative differences in the discriminative stimulus effects of low and high doses of caffeine in the rat. J Pharmacol Exp Ther 258, 857–865. - PubMed

Publication types

MeSH terms

Substances